Brand Reference: Valtrex
| Metric | Verified Benchmark | Source |
|---|---|---|
| Valacyclovir Hydrochloride RxNorm Concept ID | 73645 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1680 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $64.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $7.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $10.50 / mo | 38 Zero-PHI Verified Patient Logs |
Intestinal PEPT1-transported L-valyl prodrug achieving 3-to-5-fold higher oral bioavailability than acyclovir; selectively monophosphorylated ONLY inside HSV/VZV-infected cells by viral thymidine kinase to halt viral DNA polymerase via obligate chain termination.
Out-of-pocket price dispersion on Valacyclovir Hydrochloride spans $7.90 to $64.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.1680/unit, allowing cash buyers bypassing PBM spread pricing to retain $56.10 each month (88% reduction).
With 2.5–3.3 hours acyclovir residence kinetics and 54.5% oral (vs 15% oral acyclovir) bioavailability, Valacyclovir Hydrochloride undergoes first-pass valacyclovir hydrolase conversion; 89% renal glomerular/tubular excretion and establishes therapeutic activity over 2–4 hours episodic viral shedding arrest.
Standard adult regimens span 2000 mg PO q12h x 1 day (HSV-1 cold-sore abortive), 500 mg PO once daily (chronic suppression), 1000 mg PO TID x 7 days (zoster). Prescribers screen specifically against severe dehydration or renal impairment without dose adjustment (crystalline nephropathy prevention), while community micro-logs most frequently note headache (10% of reports), hydration requirement (8% of reports), nausea (5% of reports).
Across 38 verified cash-pay logs, Valacyclovir Hydrochloride achieves a 95.20% Worth-It rating with out-of-pocket spend averaging $10.50/mo versus $64.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 2000 mg PO q12h x 1 day (HSV-1 cold-sore abortive) for Valacyclovir Hydrochloride; monthly out-of-pocket dropped to $6.95 compared with $64.00 retail.
Completed 10 weeks on Valacyclovir Hydrochloride (500 mg PO once daily (chronic suppression)). Zero notable side effects on steady dosing.
Consistent biomarker response on 1000 mg PO TID x 7 days (zoster) Valacyclovir Hydrochloride sourced via Local Pharmacy ($9.16/mo cash pay without insurance prior authorization).